Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Nvcr save search
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
Published: 2022-03-23 (Crawled : 12:00) - novocure.com
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -2.16%
H: 2.52%
C: -0.91%
cancer phase 3 ovarian cancer
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Published: 2021-11-22 (Crawled : 12:30) - novocure.com
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -4.3%
H: 0.0%
C: 0.0%
lung cancer cancer phase 3 trial enroll
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -4.1%
H: 0.0%
C: -4.24%
cancer phase 3 ovarian cancer trial enroll
Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Published: 2021-05-24 (Crawled : 14:00) - globenewswire.com
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -1.44%
H: 6.49%
C: 0.17%
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 0.54%
H: 3.92%
C: 1.88%
lung cancer china cancer phase 3 trial train brain metastases
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-05-18 (Crawled : 12:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 2.67%
H: 6.29%
C: 0.34%
fda lung cancer fda approval cancer phase 3 trial approval
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial dmc recommendations decades
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 13.59%
H: 7.76%
C: 7.53%
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial
First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
Published: 2020-12-10 (Crawled : 14:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -0.71%
H: 7.13%
C: 5.19%
therapy radiation therapy phase 3 trial enroll glioblastoma
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.